Anaplastic thyroid carcinoma (ATC) is the most aggressive form of thyroid cancer. Despite a relatively low prevalence, it accounts for a disproportionate number of deaths, due to its resistance to any therapeutic approach. The vast majority of ATCs is associated with oncogenic mutations of BRAF or alterations of members of the PISK signaling pathway, and has a very high frequency of TP53 mutations. Based on these genetic data, our group and Dr. Fagin's group have developed two clinically relevant mouse models of ATC by combining thyroid-targeted Tp53 loss with homozygous deletion of Pten or expression of oncogenic Braf. These mice develop with very high penetrance ATCs that display all the features of their human counterpart, including high mitotic index, pleomorphism, epithelial-mesenchymal transition, aneupioidy, local invasion, and distant metastases. The analysis of these novel models has revealed that i) several groups of genes encoding components of major signaling pathways, including mitotic kinases, are markedly overexpressed in mouse ATCs independent of their driver oncogenic alteration, and ii) despite their genetic instability, these tumors are still remarkably sensitive to the inhibition of their oncogenic driver pathway. We propose to extend these studies 1) to validate our findings in a large set of genetically annotated human anaplastic thyroid tumors, 2) to establish whether mouse and human ATCs are sensitive to mitotic kinases inhibition, and 3) to assess the ability of pharmacologic inhibitors ofthe driver oncogenic pathways to increase the efficacy of cytotoxic chemotherapy by blocking critical signaling pathways that contribute to ATC resistance to these drugs. These studies will lay the foundation for new clinical trials for ATC to be carried out during the next project period.

Public Health Relevance

Despite their relative rarity, ATCs account for a major fraction of the mortality from thyroid cancer. Medical therapy has been mostly ineffective. This application proposes to leverage novel knowledge gained from relevant in vivo models to design and test Innovative therapeutic approaches to this otherwise deadly cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Mio, Catia; Lavarone, Elisa; Conzatti, Ketty et al. (2016) MCM5 as a target of BET inhibitors in thyroid cancer cells. Endocr Relat Cancer 23:335-47
Landa, Iñigo; Ibrahimpasic, Tihana; Boucai, Laura et al. (2016) Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 126:1052-66
Mandal, Rajarsi; Chan, Timothy A (2016) Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discov 6:703-13
Champa, Devora; Orlacchio, Arturo; Patel, Bindi et al. (2016) Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis. Oncotarget 7:34453-71
Brito, Juan P; Ito, Yasuhiro; Miyauchi, Akira et al. (2016) A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid 26:144-9
Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16
Vedvyas, Yogindra; Shevlin, Enda; Zaman, Marjan et al. (2016) Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight 1:e90064
Garcia-Rendueles, Maria E R; Ricarte-Filho, Julio C; Untch, Brian R et al. (2015) NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discov 5:1178-93
Dunn, Lara; Fagin, James A (2015) Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. Nat Rev Endocrinol 11:325-7
Wiesner, Thomas; Lee, William; Obenauf, Anna C et al. (2015) Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 526:453-7

Showing the most recent 10 out of 14 publications